EPS Bio Technology (ROCO:4183) Other Current Receivables: NT$2.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4183 EPS Bio Technology Corp ROCO:4183
67 GF Score
Price NT$14.70
GF Value NT$20.20
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is EPS Bio Technology Other Current Receivables?

EPS Bio Technology ROCO:4183 -1.34% 67 Other Current Receivables is NT$2.9 Mil as of Mar. 2026. GuruFocus rates ROCO:4183 with a GF Score™ of 67/100 and a GF Value™ of NT$20.20 (Modestly Undervalued). The stock has 5 warning signs investors should review.

EPS Bio Technology's Other Current Receivables for the quarter that ended in Mar. 2026 was NT$2.9 Mil.

EPS Bio Technology's quarterly Other Current Receivables declined from Sep. 2025 (NT$5.35 Mil) to Dec. 2025 (NT$2.66 Mil) but then increased from Dec. 2025 (NT$2.66 Mil) to Mar. 2026 (NT$2.87 Mil).

EPS Bio Technology's annual Other Current Receivables increased from Dec. 2023 (NT$2.97 Mil) to Dec. 2024 (NT$3.76 Mil) but then declined from Dec. 2024 (NT$3.76 Mil) to Dec. 2025 (NT$2.66 Mil).

EPS Bio Technology Other Current Receivables Related Terms

EPS Bio Technology Other Current Receivables Historical Data

* Premium members only.

The historical data trend for EPS Bio Technology's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EPS Bio Technology Other Current Receivables Chart

EPS Bio Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.78 2.27 2.97 3.76 2.66

EPS Bio Technology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.95 4.82 5.35 2.66 2.87
ROCO:4183
67GF Score
EPS Bio Technology Corp ROCO:4183
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EPS Bio Technology Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of NT$2.9 Mil mean?
EPS Bio Technology (ROCO:4183) has a Other Current Receivables of NT$2.9 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on EPS Bio Technology and its competitors.
Is EPS Bio Technology's Other Current Receivables too high?
EPS Bio Technology's current Other Current Receivables is NT$2.9 Mil. Overall, EPS Bio Technology has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EPS Bio Technology's Other Current Receivables compare to ABT and SYK?
EPS Bio Technology's Other Current Receivables of NT$2.9 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on EPS Bio Technology and its competitors. EPS Bio Technology's current Other Current Receivables is NT$2.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EPS Bio Technology stock overvalued right now?
Based on GuruFocus' analysis, EPS Bio Technology (ROCO:4183) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$20.20, compared to a current price of NT$14.70 — trading 27.2% below its estimated fair value. The current Other Current Receivables is NT$2.9 Mil. EPS Bio Technology's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For EPS Bio Technology (ROCO:4183), the current Other Current Receivables is NT$2.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EPS Bio Technology (ROCO:4183) Overvalued in 2026?

Based on GuruFocus' analysis, EPS Bio Technology stock appears to be undervalued. The current stock price of NT$14.70 is trading 27.2% below its estimated GF Value™ of NT$20.20. GuruFocus considers EPS Bio Technology to be Modestly Undervalued.

Key valuation signals for ROCO:4183:

  • Other Current Receivables: NT$2.9 Mil
  • GF Value™: NT$20.20 vs. price of NT$14.70 (27.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EPS Bio Technology Business Description

Address No. 8, R&D 3rd Road, Hsinchu Science Park, Hsinchu, TWN, 30076
EPS Bio Technology Corp operates in medical equipment manufacturing, international trade, intellectual property, and research, design, development, manufacture and sale of blood glucose measuring system and cirrhosis testing system. Its products include Test sheet and Glucose machine. Geographically it operates in Germany, Iran, Kingdom of Saudi Arabia, Switzerland, Las Vegas, and Others with majority of the revenue deriving from Germany.
67GF Score

Get the complete analysis for ROCO:4183

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$14.70
Price
NT$20.20
GF Value